習(xí)勉副主任醫(yī)師
中山大學(xué)附屬腫瘤醫(yī)院放療科
一、基本情況 專業(yè)特長：胸腹部腫瘤尤其是食管癌、肝癌的臨床診斷、放射治療及綜合治療。 主要研究方向：1、食管癌的放射治療與綜合治療;2、放射治療新技術(shù)在肝癌的臨床應(yīng)用研究;3、鼻咽癌放療后放射誘發(fā)腫瘤的臨床研究。 專家門診時間：周二下午 二、學(xué)習(xí)及工作經(jīng)歷 1999.09-2004.06 鄭州大學(xué)醫(yī)學(xué)院臨床醫(yī)學(xué)系本科 2004.09-2007.06 中山大學(xué)腫瘤防治中心腫瘤學(xué)碩士 2010.09-2013.06 中山大學(xué)腫瘤防治中心腫瘤學(xué)博士 2007.08-2010.12 中山大學(xué)腫瘤防治中心放療科住院醫(yī)師 2011.01-2015.12 中山大學(xué)腫瘤防治中心放療科主治醫(yī)師 2016.01-至今中山大學(xué)腫瘤防治中心放療科副主任醫(yī)師 三、主持科研項目 1. 國家自然科學(xué)基金青年項目(81201748)：調(diào)強(qiáng)放射治療誘導(dǎo)鼻咽癌放療后第二惡性腫瘤發(fā)生的物理效應(yīng)和調(diào)控研究。23萬元，第1負(fù)責(zé)人; 2. 廣東省科技計劃項目(2012B061700083)：不同放療技術(shù)對鼻咽癌放療后誘發(fā)惡性腫瘤的物理效應(yīng)研究。5萬元，第1負(fù)責(zé)人; 3. 廣東省食管癌研究所科技計劃青年項目(Q201401)：局部晚期食管鱗癌多西他賽+順鉑誘導(dǎo)化療聯(lián)合同期放化療的前瞻性隨機(jī)對照Ⅱ期臨床研究。5萬元，第1負(fù)責(zé)人。 四、已發(fā)表論文(第一或通訊作者) 1) Liu SL, Xi M (corresponding author), Yang H, Yang YD, Wu YJ, Zhao L, Zhang P, Luo LL, Liu MZ. Is there a correlation between clinical complete response and pathological complete response after neoadjuvant chemoradiotherapy for esophageal squamous cell cancer Ann SurgOncol. 2016; 23(1): 273-281. 2) Liu SL, Yang H, Zhang P, Zhang L, Zhao L, Luo LL, Fu JH, Liu MZ, Xi M (corresponding author). Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: a matched case–control study. RadiotherOncol. 2015; 116(2): 262-268. 3) Zhang P, Xi M (co-first author), Zhao L, Qiu B, Liu H, Hu YH, Liu MZ. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. RadiotherOncol. 2015; 116(2): 257-261. 4) Xi M, Liu SL, Zhao L, Shen JX, Zhang L, Zhang P, Liu MZ. Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS One. 2013; 8(12): e84586. 5) Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One. 2013; 8(5): e63864. 6) Zhang P, Xi M (co-first author), Zhao L, Li QQ, He LR, Liu SL, Shen JX, Liu MZ. Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastases alone. RadiatOncol. 2014; 9(1): 256. 7) Zhang P, Xi M (co-first author), Li QQ, He LR, Liu SL, Zhao L, Shen JX, Liu MZ. The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Cancer. 2014; 5(8): 689-695. 8) Zhang P, Xi M (co-first author), Zhao L, Shen JX, Li QQ, He LR, Liu SL, Liu MZ. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma? PLoS One. 2014; 9(8): e105270. 9) Zhang P, Xi M (co-first author), Zhao L, Li QQ, He L, Liu S, Shen J, Liu MZ. Unilateral cervical nodal metastasis is an independent prognostic factor for esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective study. PLoS One. 2014; 9(6): e101332. 10) Xi M, Zhang L, Li QQ, Zhao L, Zhang R, Liu MZ. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J ApplClin Med Phys. 2013; 14(3): 4162. 11) Zhang L, Xi M (co-first author), Deng XW, Li QQ, Huang XY, Liu MZ. Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Radiat Res. 2012; 53(5): 769-776. 12) Xi M, Zhang L, Liu MZ, Deng XW, Huang XY, Liu H. Dosimetric analysis of respiratory gated radiotherapy for hepatocellular carcinoma. Med Dosim. 2011; 36(2): 213-218. 13) Xi M, Zhang L, Liu MZ, Li QQ. Radiation-induced malignancy following definitive radiotherapy for nasopharyngeal carcinoma. Ann Oncol. 2012; 23S(9): 1048p. (Abstract) 14) Xi M, Liu MZ, Wang HX, Cai L, Zhang L, Xie CF, Li QQ. Radiation-induced sarcoma in patients with nasopharyngeal carcinoma: a single-institution study. Cancer. 2010; 116(23): 5479-5486. 15) Xi M, Liu MZ, Zhang L, Li QQ, Huang XY, Liu H, Hu YH. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? RadiotherOncol. 2009; 92(2): 255-259. 16) Xi M, Liu MZ, Deng XW, Zhang L, Huang XY, Liu H, Li QQ, Hu YH, Cai L, Cui NJ. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. RadiotherOncol. 2007; 84(3): 272-278.
胸腹部腫瘤尤其是食管癌、肝癌的臨床診斷、放射治療及綜合治療。?
